Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...

Thinking about picking up some Merck KGaA shares, but wondering if the current price tag does the business justice? You're not alone. Value hunters and long-term investors keep asking the same ...

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

Merck & Co beat third-quarter (3Q) sales expectations on strong results from its pneumonia vaccine as the company works to ...

The combination of Merck's Welireg and Eisai's Lenvima has not yet shown statistical significance in extending overall ...

Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer ...

The company will begin its domestic investment by starting construction on a $3 billion pharmaceutical manufacturing site in ...

Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion ...

Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life ...

Merck and Japan's Eisai said on Wednesday they will shut down a late-stage study testing an experimental combination therapy ...